27th Sep 2021 10:58
Destiny Pharma PLC - Brighton-based clinical stage biotechnology company focused on life threatening infections - Expands clinical pipeline through new XF-73 project targeting and treating superficial skin infections caused by bacteria. Programme led by Destiny Pharma partner, China Medical System Holdings Ltd. Destiny Pharma tips it could start a similar skin infection clinical programme focused on commercial territories outside those held by CMS.
Destiny Pharma already runs a dermal programme with XF-73 focused on burns and open wounds, in collaboration with US government's National Institute of Allergy & Infectious Diseases and the Global AMR Innovation Fund.
Chief Executive Neil Clark says: "We are looking forward to the future development of this programme as well as our other infection prevention assets as we continue to build a high quality, late-stage biotechnology company."
Current stock price: 113.00 pence
Year-to-date change: up 65%
By Josie O'Brien; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
DEST.L